Recent Updates
Recently added Catalysts

Viagra

Phase 1

Erectile Dysfunction | Small molecule | Other |Pfizer, Inc.|Last Updated: Feb 1, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment47
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00904748A Relative Bioavailability Study Between Two Formulations Of Sildenafil CitratePHASE1 COMPLETED 47 — — Jan 1, 2010Mar 1, 2010Feb 1, 20211 Brazil
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Curve (AUC 0-t)
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

Area under the blood concentration-time profile from time zero to last experimentally determined concentration measured in nanograms\*hour/milliliter (ng\*hr/mL).

Maximum Plasma Concentration (Cmax)
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose

Maximum plasma concentration measured in nanograms per milliliter (ng/mL).

Secondary Endpoints
Area Under the Curve From 0 to Infinity (AUC 0-inf )
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Time to Maximum Plasma Concentration (Tmax)
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Half-life (T 1/2)
Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Test 1EXPERIMENTAL -
Test 2EXPERIMENTAL -
ReferenceACTIVE_COMPARATOR -
Interventions
NameTypeDescription
sildenafil citrate 100 mg CTDRUGsildenafil citrate 100 mg CT, single dose without water
Viagra®DRUGsildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body mass index higher or equal to 18,5 and lower or equal than 29,9 kg/m2. * Good health conditions or without significant disease, at medical discretion, according to the rules defined in the Protocol, and evaluations undergone: clinical history, pulse and blood pressure mea...

Countries:Brazil
Unlock Eligibility Criteria